Bachem Holding AG Class B (CH:BANB)
:BANB
Want to see CH:BANB full AI Analyst Report?
Top Page
Bachem Holding AG
(BANB)
Select Model
Select Model
Rating:77Outperform
Price Target:
CHF92.00
▲(31.15% Upside)
Action:Upgraded
Date:05/07/26
The score is driven primarily by a very strong, low-leverage balance sheet and solid profitability, partially tempered by persistent negative free cash flow and uneven cash conversion. Technicals are constructive with clear trend strength, but near-overbought signals add some short-term risk. Valuation is supportive with a relatively low P/E and a modest dividend yield.
Positive Factors
Very conservative balance sheet; minimal leverage
Extremely low leverage provides durable financial flexibility, reducing bankruptcy and refinancing risk over the medium term. A strong equity base and minimal debt support investment in capacity, long-term supply contracts and R&D without reliance on cyclical capital markets, aiding stability.
Negative Factors
Persistent negative free cash flow since 2021
Repeated negative free cash flow over multiple years signals that capex, working-capital or investment needs exceed operating cash generation. Over the medium term this can constrain self-funded growth, increase reliance on external financing and limit durable free-cash availability.
Read all positive and negative factors
Positive Factors
Negative Factors
Very conservative balance sheet; minimal leverage
Extremely low leverage provides durable financial flexibility, reducing bankruptcy and refinancing risk over the medium term. A strong equity base and minimal debt support investment in capacity, long-term supply contracts and R&D without reliance on cyclical capital markets, aiding stability.
Read all positive factors
Bachem Holding AG (BANB) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF5.65B
Dividend Yield1.43%
Average Volume (3M)109.83K
Price to Earnings (P/E)11.4
Beta (1Y)0.77
Revenue Growth14.84%
EPS Growth23.77%
CountryCH
Employees2,207
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)1.99
Shares Outstanding75,000,000
10 Day Avg. Volume97,857
30 Day Avg. Volume109,830
Financial Highlights & Ratios
PEG Ratio1.27
Price to Book (P/B)3.08
Price to Sales (P/S)6.46
P/FCF Ratio-93.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF84.20Price Target Upside20.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)2.39
Revenue Forecast (FY)CHF950.60M
Bachem Holding AG Business Overview & Revenue Model
Company Description
Bachem Holding AG provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. The company engages in the development, production, and regulatory support of peptide activ...
How the Company Makes Money
Bachem primarily makes money by selling peptide-based pharmaceutical ingredients and by providing contract development and manufacturing services. A major revenue stream is the manufacture and supply of peptide APIs for customers’ marketed drugs (...
Bachem Holding AG Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
90
Very Positive
Cash Flow
55
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 695.07M | 605.26M | 577.32M | 531.74M | 503.23M |
| Gross Profit | 199.73M | 182.56M | 176.96M | 171.28M | 166.73M |
| EBITDA | 189.88M | 178.76M | 163.28M | 160.54M | 156.47M |
| Net Income | 148.79M | 120.25M | 111.86M | 100.68M | 114.68M |
Balance Sheet | |||||
| Total Assets | 2.11B | 1.92B | 1.68B | 1.38B | 1.30B |
| Cash, Cash Equivalents and Short-Term Investments | 30.99M | 95.20M | 298.53M | 268.43M | 442.36M |
| Total Debt | 57.39M | 290.00K | 401.00K | 691.00K | 20.86M |
| Total Liabilities | 650.41M | 531.88M | 362.36M | 214.21M | 177.50M |
| Stockholders Equity | 1.46B | 1.39B | 1.32B | 1.17B | 1.12B |
Cash Flow | |||||
| Free Cash Flow | -48.20M | -138.30M | -18.54M | -49.76M | -19.66M |
| Operating Cash Flow | 271.36M | 146.32M | 249.86M | 92.59M | 97.16M |
| Investing Cash Flow | -325.22M | -148.88M | -170.81M | -63.17M | -469.13M |
| Financing Cash Flow | -9.52M | -61.26M | 48.69M | -86.93M | 437.58M |
Bachem Holding AG Technical Analysis
Positive
70.15
Price Trends
62.95
Positive
61.37
Positive
60.98
Positive
Market Momentum
2.54
Negative
61.04
Neutral
68.15
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:BANB, the sentiment is Positive. The current price of 70.15 is above the 20-day moving average (MA) of 65.80, above the 50-day MA of 62.95, and above the 200-day MA of 60.98, indicating a bullish trend. The MACD of 2.54 indicates Negative momentum. The RSI at 61.04 is Neutral, neither overbought nor oversold. The STOCH value of 68.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:BANB.
Bachem Holding AG Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | CHF5.65B | 11.37 | 9.76% | 1.43% | 14.84% | 23.77% | |
70 Outperform | CHF4.04B | 7.66 | 27.15% | 0.67% | 27.63% | 160.67% | |
62 Neutral | CHF3.56B | 7.90 | 15.79% | 0.51% | 2.57% | 4.31% | |
61 Neutral | CHF4.11B | 13.11 | ― | 2.36% | 5.47% | -0.96% | |
56 Neutral | CHF31.99B | 19.54 | ― | 0.75% | -0.65% | -143.04% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | CHF1.23B | 43.00 | ― | ― | 13.85% | -7.03% |
* General Sector Average
CH:BANB
Bachem Holding AG
75.35
23.52
45.37%
CH:LONN
Lonza Group Ltd
469.40
-98.25
-17.31%
CH:SFZN
Siegfried Holding AG
78.90
-16.81
-17.56%
CH:YPSN
Ypsomed Holding AG
296.60
-63.49
-17.63%
CH:PPGN
PolyPeptide Group AG
37.35
17.63
89.40%
CH:GALE
Galenica AG
82.40
-1.46
-1.74%
Bachem Holding AG Corporate Events
Bachem CEO Assumes Dual Role as CCO Departs
May 5, 2026
Bachem has announced that Chief Commercial Officer Torsten Wöhr will leave the company to pursue a new professional opportunity, prompting a reshuffle at the top of the organization. Effective May 25, 2026, CEO Anne‑Kathrin Stoller will...
Bachem AGM Backs Board Proposals and Confirms CHF 0.90 Dividend
Apr 29, 2026
Bachem shareholders endorsed all proposals put forward at the 2026 Annual General Meeting, with 78.3% of voting shares represented, and approved a dividend of CHF 0.90 per share to be paid on May 6, 2026, alongside the adoption of the 2025 annual ...
Bachem Secures CHF 500 Million Credit Facility to Drive Strategic Growth
Apr 27, 2026
Bachem Holding AG has secured a CHF 500 million syndicated revolving credit facility with a five-year term, arranged by UBS Switzerland AG and a consortium of domestic and international banks, with an option to increase the facility by an addition...
Bachem lifts profit and dividend as heavy investments expand peptide capacity
Mar 12, 2026
Bachem reported a robust 2025 performance, with sales rising 14.8% to CHF 695.1 million and EBITDA up 21.8% to CHF 214.7 million, lifting the EBITDA margin to 30.9% and prompting the board to propose a higher dividend of CHF 0.90 per share. Growth...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.